Robert E. Landry, EVP Finance CFO at REGENERON PHARMACEUTICALS, INC. (REGN), sold 15,555 shares at $602.38 ($9.3M) on 2020-06-09, disclosed to the SEC on 2020-06-10.
Open-market sale of $9.3M REGN by EVP Finance CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $592.40 | 1,811 | $1.1M | 11.5% |
| 2 | $592.43 | 1,086 | $643K | 6.9% |
| 3 | $592.43 | 2,536 | $1.5M | 16.1% |
| 4 | $592.43 | 1,630 | $966K | 10.3% |
| 5 | $602.38 | 110 | $66K | 0.7% |
| 6 | $602.38 | 110 |
| $66K |
| 0.7% |
| 7 | $603.68 | 131 | $79K | 0.8% |
| 8 | $603.68 | 131 | $79K | 0.8% |
| 9 | $604.14 | 50 | $30K | 0.3% |
| 10 | $605.14 | 289 | $175K | 1.9% |
| 11 | $605.14 | 289 | $175K | 1.9% |
| 12 | $606.79 | 353 | $214K | 2.3% |
| 13 | $606.79 | 353 | $214K | 2.3% |
| 14 | $607.47 | 619 | $376K | 4.0% |
| 15 | $607.47 | 619 | $376K | 4.0% |
| 16 | $608.50 | 1,511 | $919K | 9.8% |
| 17 | $608.50 | 1,511 | $919K | 9.8% |
| 18 | $609.53 | 681 | $415K | 4.4% |
| 19 | $609.53 | 681 | $415K | 4.4% |
| 20 | $610.25 | 527 | $322K | 3.4% |
| 21 | $610.25 | 527 | $322K | 3.4% |
| Total | $600.94 avg | 15,555 | $9.3M | 100% |
| Filing → |
| REGN | SELL | 2023-08-25 | $188K | — | Filing → |
| REGN | SELL | 2023-03-29 | $1.8M | — | Filing → |
| REGN | SELL | 2023-02-07 | $2.1M | — | Filing → |